Acta Univ. Palacki. Olomuc., Fac. Med. Volume 142, 1999

RECENT APPROACHES IN THE TREATMENT OF HODGKIN’S LYMPHOMA

Luděk Raida
Haemato-oncology Department of University Hospital, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic

factorsAn aim has been to find the optimal therapeutic approach for each patient suffering from Hodgkin s lymphoma.The disease with 80% curability rate presents the great success of clinical oncology. There is no doubt that thedevelopment and improvement of therapeutic approaches described in this article has contributed to the excellentresults achieved in the last twenty years. But a lot of problems still remain to be solved by haemato-oncologistsdespite such progress in the treatment. The most important tasks are: 1. to increase the curability of advancedstages, 2. to improve therapeutic results in refractory and relapsing patients, 3. to eliminate or decrease the latetoxicity particularly in the favourable early and intermediate stages.

Keywords: Hodgkin’s disease, Radiotherapy, Chemotherapy, High-dose chemotherapy, Transplantation, Prognostic

Published: July 1, 1999  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Raida, L. (1999). RECENT APPROACHES IN THE TREATMENT OF HODGKIN’S LYMPHOMA. Biomedical papers, 142(1), 
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ahmed T., Lake D. E., Beer M. et al. (1997) Single and double autotransplants for relapsing refrectory Hodgkin.s disease: Results of two consecutive trials. Bone Marrow Transplant, 19, 449.54. Go to original source... Go to PubMed...
    2. Bonadonna G., Zucali R., Monfardini S. et al. (1975) Combination chemotherapy of Hodgkin.s disease with doxorubicin, bleomycin, vinblastine and imidazole carboximide versus MOPP. Cancer 36, 252.59. Go to original source... Go to PubMed...
    3. Carde P., Hagenbeek A., Hayat M. et al. (1993) Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin s disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J. Clin. Oncol. 11, 2258.2272. Go to original source... Go to PubMed...
    4. Carella A. M. et al. (1991) Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin.s disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant, 8, 99.103. Go to PubMed...
    5. Connors J. M., Klimo P., Adams G. et al. (1997) Treatment of advanced Hodgkin.s disease with chemotherapy . Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 15, 1638.1645. Go to original source... Go to PubMed...
    6. De Vita V. T., Simon R. M., Hubbard S. M. et al. (1980) Curability of advanced Hodgkin.s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92, 587.595. Go to original source... Go to PubMed...
    7. Diehl V., Loeffler M., Pfreundschuh M. et al (1995) For German Hodgkin.s Study Group: Further Chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin.s disease. Ann Oncol 6, 901.910. Go to original source... Go to PubMed...
    8. Diehl V., Franklin J., Hasenclever D. et al. (1998) BEACOPP: A new regimen for advanced Hodgkin s disease. Ann. Oncol. 9 (Suppl. 5): S 67.71. Go to original source... Go to PubMed...
    9. Diehl V., Franklin J., Hasenclever D, et al. (1998) BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin.s lymphoma: Interim report from a trial of the German Hodgkin.s lymphoma Study Group. J. Clin. Oncol., No. 12 (December), Vol. 16, pp 3810.3821. Go to original source... Go to PubMed...
    10. Duhmke E., Diehl V., Loeffler M. et al. (1996) Randomized trial with early-stage Hodgkin.s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int. J. Radiat. Oncol. Biol. Phys., 36, 305.310. Go to original source... Go to PubMed...
    11. Engert A., Diehl V., Schnell R. et al. (1997) A phase I study of an anti CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin.s lymphoma. Blood, 89 (2): 403.410. Go to original source...
    12. Falini B., Bolognesi A., Flenghi L. et al. (1992) Response of refractory Hodgkin.s disease to monoclonal anti-CD30 immunotoxin. Lancet, 339, 1195.1196. Go to original source... Go to PubMed...
    13. Gianni A. M., Siena S., Bregni M. et al. (1993) High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin.s disease . a six-year update. Ann. Oncol., 4, 889.891. Go to original source... Go to PubMed...
    14. Hansmann M. L., Zwingers T., Boeske A. et al. (1984) Clinical features of nodular paragranuloma (Hodgkin.s disease, lymphocyte predominance type, nodular). J. Cancer. Res. Clin. Oncol., 108, 321. Go to original source... Go to PubMed...
    15. Harris N. L., Jaffe E. S., Stein H. et al. (1994) A revised European . American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood, 84, 1361.1392. Go to original source...
    16. Hasenclever D., Diehl V. (1996) for the international prognostic factors project on advanced Hodgkin.s disease. A prognostic index, but no very high risk group. Ann. Oncol., 7 (Suppl 3): 21 (Abstr 65).
    17. Hartmann F., Reuner C., Jung W. et al. (1997) Treatment of refractory Hodgkin.s disease with an anti-CD16/CD30 bispecific antibody. Blood, 89, 2042.2047. Go to original source...
    18. Hornig S. J., Hope R. T. , Breslin S. et al. (1998) Brief chemotherapy (Stanford V.) and involved field radiotherapy (RT) are highly effective for advanced Hodgkin s disease. ASCO (Abstr. 59).
    19. Hornig S. J., Chao N. J., Negrin R. S. et al. (1997) High-dose therapy and autologous hemopoietic progenitor cell transplantation for recurrent or refractory Hodgkin.s disease: Analysis of the Stanford University results and prognostic indicies. Blood, 89, 801.813. Go to original source...
    20. Lister T. A., Crowther D., Sutcliffe S. B. et al. (1989) Report of committee convened to discuss the evaluation and staging of patients with Hodgkin s disease. The Cotswolds meeting. J. Clin. Oncol. 7, 1630.1636. Go to original source... Go to PubMed...
    21. Loeffler M., Hasenclever D., Diehl V. (1998) for the German Hodgkin.s Lymphoma Study Group. Model based develoment of the BEACOPP regimen for advanced stage Hodgkin.s disease. Ann. Oncol. 9 (Suppl. 5), 73.78. Go to original source... Go to PubMed...
    22. Meadows A. T., Obringer A. C., Marrero O. et al. (1989) Second malignant neoplasms following childhood Hodgkin.s disease: Treatment and splenectomy as risk factors. Med. Pedistr. Oncol., 17, 477.484. Go to original source...
    23. Ng A. K., Weeks J. C., Manch P. M. et al. (1999) Laparotomy versus no laparotomy in the management of early-stage, favourable prognosis Hodgkin.s disease: A decision analysis. J. Clin. Oncol., No. 17, No. 1 (January), pp 241.252. Go to original source... Go to PubMed...
    24. Proctor S. J. et al. (1991) A numerical prognostic index for clinical use in identification of poor risk patients with Hodgkin.s disease at diagnosis. Scottish and Newcastle Lymphoma Group (SNLG) therapy working party. Eur. J. Cancer., 27.5, 624.629. Go to original source... Go to PubMed...
    25. Raida L., Faber E., Papajik T. et al. (1999) Up-front tandem autologous peripheral blood stem cells transplantation using BEAM 400 and TMJ conditioning in patient with advanced Hodgkin .s disease with high tumor burden. Bone Marrow Transplantation, Vol. 23, Suppl. 1.
    26. Rosenberg S. A. (1996) The management of Hodgkin.s disease: Half a century of change. The Kaplan memorial lecture. Ann. Oncol. 7, 555.560. Go to original source... Go to PubMed...
    27. Santoro A., Bonfante V., Bonadonna G. et al. (1982) Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin.s disease. Ann. Intern. Med. 96, 139.143. Go to original source... Go to PubMed...
    28. Sieber M., Rueffer U., Tesch H. et al. (1997) Rapidly alternating COPP +ABV+IMEP(CAI) is equally effective as alternating COPP +ABVD(CA) for Hodgkin.s disease: Final results of two randomized trials for intermediate (HD5 protocol) and advanced (HD6 protocol) stages. American Society of Hematology 39th Annual Meeting. Blood, 90, (Abstr. 2605).
    29. Slavin S., Nagler A., Naparstek E. et al. (1998) Nonmyeloablative stem cell transplantation as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant haematologic diseases. Blood, Vol. 91, No. 3 (February 1), pp 756.763. Go to original source...
    30. Specht L. (1996) Prognostic factors in Hodgkin s disease. Semin. Radiat. Oncol., 6, 146. Go to original source... Go to PubMed...
    31. Specht L., Gray R. G., Clarke M. J. et al. (1998) Influence of more extensive radiotherapy and adjuvant chemotherapy on longterm outcome of early-stage Hodgkin.s disease: A meta-analysis of 23 randomized trials involving 3,888 patients. J. Clin. Oncol. 16, 830.843. Go to original source... Go to PubMed...
    32. Tepler I., Schwartz G., Parker K. et al. (1994) Phase I trial of an interleukin .2 fusion toxin (DAB486IL-2)in haematologic malignancies: Complete response in a patient with Hodgkin.s disease refractory to chemotherapy. Cancer, 73, 1276.1285. Go to original source... Go to PubMed...
    33. Tucker M. A., Coleman C. N., Cox R. S. et al. (1988) Risk of second cancers after treatment for Hodgkin s disease. A Engl. J. Med., 318, 76.81. Go to original source... Go to PubMed...
    34. Valagursa P., Santoro A., Forsati-Bellani F. et al. (1986) Second acute leukemia and other malignancies following treatment for Hodgkin.s disease. J. Clin. Oncol., 4, 830.837. Go to original source... Go to PubMed...
    35. Van Leeuwen F. E., Klokman W. J., Hagenbeck A. et al. (1994) Second cancer risk following Hodgkin.s disease: A 20-year follow- up study. J. Clin. Oncol., 12, 312.325. Go to original source... Go to PubMed...
    36. Viviani S., Bonadonna G., Santoro A. et al. (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin .s disease: Ten years results. J. Clin. Oncol. 14, 1421.1430. Go to original source... Go to PubMed...
    37. Wolf J., Tesch H., Parsa-Parsi R. et al. (1998) Curent clinical trials for the treatment of adult Hodgkin.s disease: Common strategies and perspectives. Ann. Oncol. 9 (Suppl. 5), 79.82. Go to original source... Go to PubMed...

    Return to the content